Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences By: Alpine Immune Sciences, Inc. via Business Wire February 26, 2024 at 16:30 PM EST Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences. Monday, March 4th, Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer will participate in an IgA Nephropathy corporate panel at 9:10 am ET/6:10 am PT during the TD Cowen 44th Annual Healthcare Conference in Boston, MA and the Company will host investor meetings the same day. Tuesday, March 12th, Remy Durand, Ph.D., Chief Business Officer will participate in a fireside chat during the Leerink Partners Global Biopharma Conference in Miami, FL at 2:20 pm ET/11:20 am PT and the Company will host investor meetings the same day. Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event. About Alpine Immune Sciences Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240226284227/en/Contacts Media and Investor Relations Contact: ir@alpineimmunesciences.com media@alpineimmunesciences.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences By: Alpine Immune Sciences, Inc. via Business Wire February 26, 2024 at 16:30 PM EST Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences. Monday, March 4th, Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer will participate in an IgA Nephropathy corporate panel at 9:10 am ET/6:10 am PT during the TD Cowen 44th Annual Healthcare Conference in Boston, MA and the Company will host investor meetings the same day. Tuesday, March 12th, Remy Durand, Ph.D., Chief Business Officer will participate in a fireside chat during the Leerink Partners Global Biopharma Conference in Miami, FL at 2:20 pm ET/11:20 am PT and the Company will host investor meetings the same day. Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event. About Alpine Immune Sciences Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240226284227/en/Contacts Media and Investor Relations Contact: ir@alpineimmunesciences.com media@alpineimmunesciences.com
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences. Monday, March 4th, Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer will participate in an IgA Nephropathy corporate panel at 9:10 am ET/6:10 am PT during the TD Cowen 44th Annual Healthcare Conference in Boston, MA and the Company will host investor meetings the same day. Tuesday, March 12th, Remy Durand, Ph.D., Chief Business Officer will participate in a fireside chat during the Leerink Partners Global Biopharma Conference in Miami, FL at 2:20 pm ET/11:20 am PT and the Company will host investor meetings the same day. Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event. About Alpine Immune Sciences Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240226284227/en/